LBSP Favicon

Leyden Labs secures €20 Million EIB funding to strengthen pandemic preparedness

Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme. The funding will support the clinical development […]

Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme.

The funding will support the clinical development of Leyden Labs’ PanFlu nasal spray, an intranasal antibody therapy designed to protect against a broad range of influenza viruses, including seasonal flu, avian flu (H5), and future respiratory threats. Unlike traditional vaccines, this approach offers direct, fast-acting protection at the site of infection: the respiratory mucosa.

With this investment, Leyden Labs takes a major step forward in preparing for future pandemics through scalable, accessible prevention strategies that complement existing vaccine efforts.

Read more here

Related posts

Algemene Rekenkamer (Court of Audit) visits LBSP

Algemene Rekenkamer (Court of Audit) visits LBSP

The Court of Audit visited LBSP to explore how science and entrepreneurship create public value, with stops at TNO, Peregrion, NTrans, and VarmX sparking discussion on biotech innovation.

Life Sciences Café June Edition

Life Sciences Café June Edition

Thank you to everyone who joined us last Thursday at Grand Café de Stal. The room was full of energy, curiosity, and conversation as we explored the next wave of biotech...